NCT00130793View on ClinicalTrials.gov

A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED)

PHASE3CompletedINTERVENTIONAL
Enrollment

368

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

November 30, 2005

Study Completion Date

November 30, 2005

Conditions
Herpes Zoster
Interventions
BIOLOGICAL

Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation

1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1

BIOLOGICAL

Comparator: zoster vaccine live (Oka/Merck) frozen formulation

1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1

All Listed Sponsors
lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00130793 - A Study to Evaluate Safety, Tolerability, and Immunogenicity of an Investigational Zoster Vaccine In Subjects With a History of Varicella (Chickenpox)(V211-010)(COMPLETED) | Biotech Hunter | Biotech Hunter